Warpechowski Paulo, Lima Gustavo G, Medeiros Cláudio M, Santos Ari Tadeu L, Kruse Marcelo, Migloransa Marcelo H, Kalil Renato A K
Institute of Cardiology of Rio Grande Do SUL/FUC, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, Porto Alegre, Brazil.
Pacing Clin Electrophysiol. 2006 Dec;29(12):1375-82. doi: 10.1111/j.1540-8159.2006.00550.x.
Atrioventricular nodal reentrant tachycardia (AVNRT) is probably the most common form of paroxysmal supraventricular tachycardia. Percutaneous catheter ablation is a technique to interrupt cardiac conduction pathways selectively. The anesthetist is challenged to provide a safe anesthetic which takes into account the electrophysiologist's requirements for minimal cardiac conduction interference. Propofol is an ideal drug. However, previous studies have shown that the infusion of propofol has sometimes been associated with bradyarrhythmias or conversion of arrhythmias to sinusal rhythm. The purpose of this report is to verify the interferences of propofol in the electrophysiological properties of the atrioventricular (AV) node conduction system in patients with AVNRT.
Patients were randomly assigned to receive either a placebo or propofol at sedative doses. An electrophysiological study was performed consisting of measuring the anterograde (AERPFP) and retrograde effective refractory period of the fast (RERPFP) and the anterograde effective refractory period of the slow (AERPSP) AV nodal pathway. Reciprocating tachycardia was induced and the cycle length (CL) and atrial-His (AH), His-ventricular (HV), and ventriculoatrial (VA) intervals were measured.
Propofol did not cause alteration (P > 0.05) in the AERPFP or RERPFP and the AERPSP AV nodal pathway. The AH, HV, and VA intervals were not affected. Sustained reciprocating tachycardia could be induced in the all patients. All slow pathways were successfully identified and ablated.
Propofol has no effect on the electrophysiological properties of the AV node conduction system. It is thus a suitable anesthetic agent for use in patients undergoing ablative procedures.
房室结折返性心动过速(AVNRT)可能是阵发性室上性心动过速最常见的形式。经皮导管消融是一种选择性中断心脏传导通路的技术。麻醉医生面临的挑战是提供一种安全的麻醉方法,同时要考虑到电生理学家对最小程度心脏传导干扰的要求。丙泊酚是一种理想的药物。然而,先前的研究表明,输注丙泊酚有时会伴有缓慢性心律失常或心律失常转复为窦性心律。本报告的目的是验证丙泊酚对AVNRT患者房室(AV)结传导系统电生理特性的干扰。
患者被随机分配接受安慰剂或镇静剂量的丙泊酚。进行了一项电生理研究,包括测量快速房室结通路的前向有效不应期(AERPFP)和逆向有效不应期(RERPFP)以及缓慢房室结通路的前向有效不应期(AERPSP)。诱发折返性心动过速并测量心动周期长度(CL)以及心房-希氏束(AH)、希氏束-心室(HV)和心室-心房(VA)间期。
丙泊酚未导致AERPFP、RERPFP和AERPSP房室结通路发生改变(P>0.05)。AH、HV和VA间期未受影响。所有患者均可诱发持续性折返性心动过速。所有慢径路均成功识别并消融。
丙泊酚对房室结传导系统的电生理特性无影响。因此,它是用于接受消融手术患者的合适麻醉剂。